Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 1499Cisplatin 1434Paclitaxel 1339Radiotherapy 1310Carboplatin 1266Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 697Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × orantinib × Clear all
NCT00024206 2013-01-23

SU6668 in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00784290 2012-03-26

Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma

Taiho Pharmaceutical Co., Ltd.

Phase 1/2 Completed
35 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡